Tagged: #PBS

26
Apr
2013
 
A treatment option for advanced bowel cancer patients has been recommended for PBS listing by the Pharmaceutical Benefits Advisory Committee (PBAC).
 
The Committee, who advise the Health Minister, determined that Vectibix (panitumumab) should be approved for use alone or in combination with FOLFIRI (5-FU + Irinotecan) when first-line chemotherapy has failed.
Published in Latest News
01
Nov
2011
 
Approximately 800 patients per year are expected to benefit from today's extended Pharmaceutical Benefits Scheme (PBS) listing of Xeloda® (capecitabine).
 
The treatment is now available on the PBS for patients with advanced bowel cancer – stage III (Dukes C) - in combination with another chemotherapy, oxaliplatin. The combination therapy is known as XELOX.
Published in Latest News
31
Aug
2011
 
Bowel cancer patients eligible to receive Erbitux will now be able to access the treatment without worrying about its impact on their already stretched finances.
 
Erbitux® (cetuximab) is available on the Pharmaceutical Benefits Scheme from 1 September 2011 for patients living with KRAS wild-type metastatic bowel cancer who have not responded to first line chemotherapy.
Published in Latest News
21
Jun
2011
 
Bowel Cancer Australia said today's decision to list Erbitux on the PBS from 1 September 2011 will be a huge relief for the 2,700 individuals literally fighting for their life, but it remains concerned about the approval process.
 
Julien Wiggins, chief executive officer of Bowel Cancer Australia said bowel cancer families have enough emotional and physical challenges to manage without worrying about whether they can afford to stay alive.
 
"The PBS (Pharmaceutical Benefits Scheme) listing of Erbitux means the financial burden of this treatment has now been alleviated and that is great news," he added.
Published in Latest News
Page 2 of 2
Support Bowel Cancer Australia
Bowel Cancer Australia Social Media